Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK

Xoma, Biogen, Agenus, and GSK could all loom large in health care headlines this morning.

Mar 5, 2014 at 9:00AM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Let's take a look at four stocks that could make health care headlines this morning -- Xoma (NASDAQ:XOMA), Biogen Idec (NASDAQ:BIIB), Agenus (NASDAQ:AGEN), and GlaxoSmithKline (NYSE:GSK)

Xoma stops testing arthritis drug
Shares of Xoma (NASDAQ:XOMA) may be in for a rough ride this morning, after the company announced that it would not proceed with late-stage studies of gevokizumab as an arthritis treatment, after two mid-stage studies failed to show a significant benefit in patients. Gevokizumab is the company's lead drug candidate.

However, that doesn't mean that gevokizumab is finished -- Xoma (NASDAQ:XOMA) is still testing the drug as a potential treatment for a variety of other indications, including acne, autoimmune ear disease, and non-infective scleritus. Xoma (NASDAQ:XOMA) doesn't have any marketed products, and generates the majority of its revenue from various license, collaborative, and contract fees.

Biogen acquires the rights to Eisai's Alzheimer's drugs
Meanwhile, Biogen Idec (NASDAQ:BIIB) just acquired the rights to Eisai's (NASDAQOTH:ESALY) experimental Alzheimer's treatments E2609 and BAN2401. Biogen (NASDAQ:BIIB) will pay Eisai (NASDAQOTH:ESALY) an upfront payment and fixed milestone payments based on approval and commercialization. Biogen (NASDAQ:BIIB) and Eisai (NASDAQOTH:ESALY) will share development expenses and co-promote the two drugs. The two companies will share the revenue and profits from the two drugs if they are approved. The agreement also grants Eisai (NASDAQOTH:ESALY) an option to jointly develop and market two of Biogen's (NASDAQ:BIIB) experimental treatments for Alzheimer's disease.

This is an interesting change of pace for Biogen (NASDAQ:BIIB), which is primarily known for its multiple sclerosis (MS) drugs Avonex, Tysabri, and Tecfidera. Tecfidera, in particular, is expected to become a blockbuster drug with peak sales of $3.8 billion.

Eisai (NASDAQOTH:ESALY), on the other hand, was the original manufacturer of Aricept, the world's best-selling Alzheimer's treatment before it went off patent in 2010. Aricept helped slow cognitive decline, but failed to address the root cause of the disease, which is commonly believed to be caused by the formation of beta amyloid "brain plaques."

The deal may face skepticism from investors who remember Johnson & Johnson/Pfizer/Elan's bapineuzumab and Eli Lilly's solanezumab, two monoclonal antibodies which were intended to clear away brain plaques but failed to produce any significant results. Eisai's (NASDAQOTH:ESALY) E2609 is a BACE inhibitor, similar to Eli Lilly's failed Alzheimer's drug LY2886721, and BAN2401 is a monoclonal antibody like bapineuzumab and solanezumab.

Agenus reports fourth quarter earnings
Agenus (NASDAQ:AGEN) -- which focuses on various experimental treatments for diseases such as malaria, cancer, Alzheimer's disease, and genital herpes through partnerships with GSK (NYSE:GSK), Johnson & Johnson, and Pfizer -- just reported its fourth quarter and full year earnings.

Agenus (NASDAQ:AGEN), which doesn't have any marketed products, reported a net loss of $0.16 per share, or $5.8 million for the quarter, compared to a loss of $0.23 per share, or $5.6 million, in the prior year quarter. For the full year, Agenus (NASDAQ:AGEN) reported a net loss of $1.12 per share, or $33.2 million, compared to a loss of $0.51 per share, or $12.1 million, in the previous year. Agenus (NASDAQ:AGEN) finished fiscal 2013 with $27.4 million in cash, but it gained net proceeds of approximately $56 million from a public offering completed in the first quarter of 2014.

Agenus' (NASDAQ:AGEN) most promising product is its QS-21 Stimulon Adjuvant, which can boost the effectiveness of various vaccines. GSK (NYSE:GSK)is currently partnered with Agenus (NASDAQ:AGEN) for four indications in late-stage trials using QS-21 -- malaria, non-small cell lung cancer, melanoma, and shingles. Pfizer and Johnson & Johnson are partnered with Agenus (NASDAQ:AGEN) in an Alzheimer's indication which is currently in phase 2 trials. Shares of Agenus (NASDAQ:AGEN) are up nearly 90% over the past three months on optimism regarding its late-stage pipeline.

Agenus (NASDAQ:AGEN) and Ludwig Cancer Research also announced the advancement of three monoclonal antibody checkpoint modulators into preclinical development. These modulators -- two GITR agonists and a CTLA-4 antagonist -- target cell surface checkpoint proteins which can control immune responses, and represent another way for Agenus (NASDAQ:AGEN) to diversify its pipeline.

GSK's HIV drug GSK744 could be a game changer
Last but not least, GSK's (NYSE:GSK) experimental HIV drug GSK744 generated a lot of excitement at an AIDS conference yesterday. According to an Associated Press report, researchers reported that the injected drug, which crystallizes in the blood and is released over a longer period than traditional HIV drugs, achieved "100% protection" from HIV in two studies with monkeys.

This means that if the drug passes clinical trials and is approved, it could allow HIV to be prevented through periodic injections, rather than condoms, in a similar manner as birth control pills. A drug that is already known to reduce the chance of HIV spreading between sexual partners is Gilead Sciences' Truvada.

GSK744 is currently being developed by ViiV Healthcare, a joint venture between GSK (NYSE:GSK), Pfizer, and Shionogi. GSK owns 76.5% of the joint venture, while Pfizer and Shionogi respectively own 13.5% and 10%.

One more hidden gem to watch this morning...
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Leo Sun owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers